GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Teladoc Health Inc (NYSE:TDOC) » Definitions » Cash Flow from Financing

Teladoc Health (Teladoc Health) Cash Flow from Financing : $11 Mil (TTM As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Teladoc Health Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2023, Teladoc Health paid $0 Mil more to buy back shares than it received from issuing new shares. It received $0 Mil from issuing more debt. It paid $0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0 Mil from paying cash dividends to shareholders. It received $0 Mil on other financial activities. In all, Teladoc Health spent $0 Mil on financial activities for the three months ended in Dec. 2023.


Teladoc Health Cash Flow from Financing Historical Data

The historical data trend for Teladoc Health's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Teladoc Health Cash Flow from Financing Chart

Teladoc Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 35.09 859.14 40.95 6.50 10.85

Teladoc Health Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.38 3.35 4.21 5.07 -1.78

Teladoc Health Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Teladoc Health's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Teladoc Health's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Teladoc Health  (NYSE:TDOC) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Teladoc Health's issuance of stock for the three months ended in Dec. 2023 was $0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Teladoc Health's repurchase of stock for the three months ended in Dec. 2023 was $0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Teladoc Health's net issuance of debt for the three months ended in Dec. 2023 was $0 Mil. Teladoc Health received $0 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Teladoc Health's net issuance of preferred for the three months ended in Dec. 2023 was $0 Mil. Teladoc Health paid $0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Teladoc Health's cash flow for dividends for the three months ended in Dec. 2023 was $0 Mil. Teladoc Health received $0 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Teladoc Health's other financing for the three months ended in Dec. 2023 was $0 Mil. Teladoc Health received $0 Mil on other financial activities.


Teladoc Health Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Teladoc Health's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Teladoc Health (Teladoc Health) Business Description

Traded in Other Exchanges
Address
2 Manhattanville Road, Suite 203, Purchase, NY, USA, 10577
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members; it has also started to market directly to consumers while expanding its service portfolio.
Executives
Daniel Trencher officer: SVP Corporate Strategy 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577
Vidya Raman-tangella officer: Chief Medical Officer 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577
Karen L Daniel director 2801 80TH STREET, KENOSHA WI 53141
Jason N Gorevic director, officer: President & CEO
Andrew Turitz officer: SVP - Business Development C/O TELADOC, INC., 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577
Stephany Verstraete officer: Chief Marketing Officer C/O TELADOC, INC., 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577
Adam C Vandervoort officer: Chief Legal Officer, Secretary 485 MADISON AVENUE, NEW YORK NY 10022
Mala Murthy officer: Chief Financial Officer C/O TELADOC HEALTH, INC., 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577
Richard J Napolitano officer: Chief Accounting Officer MSCI INC., 7 WORLD TRADE CENTER, 250 GREENWICH STREET, 49TH FLOOR, NEW YORK NY 10007
Arnnon Geshuri officer: Chief Human Resources Officer 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577
Laizer Kornwasser officer: PRESIDENT, ENTERPRISE GROWTH 100 PARSONS POND DRIVE, FRANKLIN LAKES NJ 07417
Michael Willem Waters officer: CHIEF OPERATING OFFICER 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577
Jason Eric Evans director 310 SEVEN SPRINGS WAY, SUITE 500, BRENTWOOD TN 37027
Claus Torp Jensen officer: Chief Innovation Officer 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577
Sandra L Fenwick director C/O TELADOC HEALTH, INC., 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577